貴州百靈(002424.SZ):兩新藥獲得獲得三項國外專利證書
格隆匯10月28日丨貴州百靈(002424.SZ)宣佈,近日,公司收到由歐亞專利組織、韓國知識產權局、澳大利亞知識產權局頒發的專利證書。
其中,歐亞專利證書及韓國專利證書專利名稱均為嘌呤基-N-羥基嘧啶甲酰胺衍生物及其製備方法和用途。該專利是公司與四川大學華西醫院共同研發用於治療血液瘤的化藥1.1類新藥注射用甲磺酸普依司他項目的化合物專利。
澳大利亞專利證書專利名稱為4位取代的香豆素衍生物及其製備方法和用途。該專利是公司與四川大學華西醫院共同研發用於抗腫瘤的化藥1.1類新藥候選藥物GZ50項目的化合物專利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.